Work

A first-in-human phase I study to evaluate the pan-PI3K inhibitor GDC-0941 administered QD or BID in patients with advanced solid tumors

Year: 2009

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2009.27.15_suppl.3501

Authors: A. J. Wagner, D. H. Von Hoff, P. M. LoRusso, R. Tibes, K. E. Mazina, J. A. Ware, Y. Yan, M. K. Derynck, G. D. Demetri

Institutions: Genentech, The Barbara Ann Karmanos Cancer Institute, Dana-Farber Cancer Institute

Language: English

Topic: PI3K/AKT/mTOR signaling in cancer

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2220670435

Cites:

Cited by: 64

Related to: 10